Ro5


Ro5 is a company dedicated to accelerating drug discovery and clinical trial processes through advanced AI, data science, and analytics. They develop AI platforms and provide professional services to pharma, biotech, and academic institutions, with a focus on de novo drug discovery, bioactivity, ADMET, and knowledge graph capabilities. Their mission is to address the urgent need for faster disease treatment solutions.

Industries

artificial-intelligence
biotechnology
clinical-trials
health-care
machine-learning
pharmaceutical

Nr. of Employees

small (1-50)

Ro5

2801 Gateway Drive, Irving, Texas 75063


Patents

System and method for feedback-driven automated drug discovery

US-12248885-B2

View Details

System and method for molecular reconstruction from molecular probability distributions

US-12223435-B2

View Details

System and method for the contextualization of molecules

US-11710049-B2

View Details

System and method for de novo drug discovery

US-11615324-B2

View Details

System and method for the latent space optimization of generative machine learning models

US-11610139-B2

View Details

System and method for accelerating FEP methods using a 3D-restricted variational autoencoder

US-11568961-B2

View Details
View All Patents

Products

AI platforms for molecular analytics and structure-based screening

Web-deployed platforms that perform molecular representation, structure-based screening, bioactivity prediction, and data integration through knowledge-graph workspaces to support discovery and prospective experimental validation.


Services

Tailored consulting and delivery of AI-enabled tools and workflows to support drug discovery stages and clinical-trial analytics; services can be individual tools or comprehensive end-to-end programs delivered by in-house scientists.

Expertise Areas

  • De novo drug discovery
  • Bioactivity and protein–ligand prediction
  • ADMET modeling
  • Knowledge graph–enabled data integration
  • Show More (5)

Key Technologies

  • Knowledge graphs
  • Structure-based deep learning
  • Point-cloud machine learning for molecular data
  • 3D variational / conditional generative adversarial networks
  • Show More (6)

News & Updates

Announcement of the release of the SpectraView v1 web application.

Announcement of the HydraScreen web application in support of the preprint.

Introduction of HydraScreen, an advanced tool for drug discovery.

A study combining SpectraView with other methods for faster hit identification.

Discussion of future lab technology involving software vendors and pharma companies.

Ro5 used HydraScreen to screen compounds and compare performance.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.